Csl Limited · ASX:CSL
Csl — Investor Presentation (March 2003)
15 slides from Csl's investor presentation, March 2003
Slide 1: CSL Limited
CSL Limited
Slide 2: History
History S Australia’s leading biopharmaceutical company S Biologicals specialist S Founded in 1916 S Privatisation 1994 (Australian Stock Exchange) S Two strategic M & A transactions – 2000 ZLB AG Switzerland – 2001 Nabi Plasma Centers (ZLB Plasma Services)
Slide 3: Strategy
Strategy S Protein Focus – plasma products – vaccines – biotech S Springboard Australian and Swiss excellence into global competitiveness S Invest in quality (GMP) assets S Innovation particularly immunology S Creative partnering S Execution and integration of strategic acquisitions S Financial disc
Slide 4: The Business Today
The Business Today 2000/01 Sales by Business Unit US$430m Animal Health 7% Biosciences 13% Biopharmaceuticals 80%
Slide 5: The Business Today
The Business Today Biopharmaceutical Sales US $344m Pharmaceutical (mainly vaccines) 28% Plasma Products (mainly IVIG) 72%
Slide 6: Performance: Total Revenues
Performance Total Revenues $500 $450 $400 $350 $300 US Million $250 $200 $150 $100 $50 $0 1998 1999 2000 2001 Year ending 30 June
Slide 7: Performance: EBITDA
Performance EBITDA $120 $100 $80 US Million $60 $40 $20 $0 1998 1999 2000 2001 Year ending 30 June
Slide 8: Performance: Operating PAT (pre Goodwill)
Performance Operating PAT (pre Goodwill) $60 $50 $40 US Million $30 $20 $10 $0 1998 1999 2000 2001 Year ending 30 June
Slide 9: Drivers of Growth: Plasma Products
Drivers of Growth Plasma Products S Secure greater plasma volume S Maintain plant quality and increase scale in Switzerland and Australia S Increase value extraction S Commitment to USA and selected European, Asian and Australian markets S New products – Improved IVIG – Fibrin Bandage (partner with
Slide 10: Drivers of Growth: Biopharmaceutical
Drivers of Growth Biopharmaceutical S Build on Influenza Vaccine Expertise - Fluvax™ - Southern hemisphere and Export - Flumist™ (Australian partner of AVIRON) S Market-partnered products in Australian/NZ S Biotech innovation - ISCOM adjuvant ® - Recombinant antigens
Slide 11: Drivers of Growth: Cell Culture and Animal Health
Drivers of Growth Cell Culture S Focus on industry segment (JRH Biosciences) Animal Health S Specialist vaccine company S Leverage Australian innovation S Expansion in USA (Biocor Animal Health)
Slide 12: Value from Innovation: Novel Protein Products in the Clinic
Value from Innovation Novel Protein Products in the Clinic S HPV Vaccine – licensed to Merck Inc. S ISCOM based immunotherapeutics - CerVax16 - NYESO-1 – collaboration with Ludwig Institute for Cancer Research - (CHIRON-license for Hepatitis C) S Anti D products - plasma - Rhophylac™ - recombinant S
Slide 13: Value from Innovation – Partnering with Merck
Value from Innovation – Partnering with Merck S Human Papillomavirus (HPV) pivotal role in cervical cancer - 470,000 cases annually - 5 year survival rate of 50-70% - 50 million adolescent and adult females in the US at risk S Quadrivalent Vaccine: Recombinant Virus-Like Particles (Types 6, 11, 16,
Slide 14: Financial Attributes
Financial Attributes S Revenue growth S Strong cash flows S Conservative gearing S Swiss (ZLB AG) 10 yrs tax relief S Consistent performance
Slide 15: Summary
Summary S Company poised for continuing expansion S Specialist focus S Recognized innovation capability S Ability to form valuable alliances S History of successful M & A activity S Delivery on financials